Compare Google Inc (GOOG) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Alphabet (GOOG) trades at $349.52, up 0.16% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust revenue growth to $402.84 billion in 2025, with net income surging to $132.17 billion and a net margin of 32.8%. Recent earnings beats and a consensus analyst price target of $435.29 highlight investor confidence, though high capital expenditures and legal challenges present near-term risks.

The outlook for GOOG remains positive driven by AI and cloud expansion, with projected 2026 revenue of $445.9 billion. However, rising capex leading to negative free cash flow projections and ongoing securities lawsuits pose significant risks. The stock's current valuation metrics, including a P/E of 17.54, suggest room for growth if execution continues, but investors should weigh these factors against the competitive and regulatory landscape.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.